Liver transplantation in developing countries

Dao D. Liver transplantation in developing countries. Hepatology Forum 2022; 3(3):103–107.

How to cite this article: Ozturk NB, Muhammad H, Gurakar M, Aslan A, Gurakar A, Dao D. Liver transplantation in developing countries. Hepatology Forum 2022; 3(3):103–107.

Received: June 30, 2022; Accepted: July 05, 2022; Available online: September 23, 2022

Corresponding author: Ahmet Gurakar; Liver Transplant, Professor of Medicine, Section of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross Research Building, Suite 918, Baltimore, MD 21205
Phone: +90 410 641 3369; e-mail: agurakar1@jhmi.edu

Hepatology Forum - Available online at www.hepatologyforum.org

Introduction

Liver transplantation (LT) is an established and only definitive treatment for end-stage liver disease (ESLD). With the increasing incidence and prevalence of ESLD, demand for donor liver grafts continues to increase, making the liver a scarce resource.[1,2] Despite the exponential increase in patients requiring liver, available organ donors have increased minimally.[3] Challenges arise when there is a shortage of suitable donor organs to supply the patients requiring the LT. Deceased-donor liver transplantation (DDLT) is the ideal and preferred method for LT. However, with the scarcity of deceased-donor organs to meet the need of patients, several solutions were developed to expand the donor pool and to maximize the utilization of liver allografts, such as using extended criteria donor grafts, split LT, donation after cardiac death (also known as non-heart beating donors), auxiliary transplants, domino LT, and living-donor liver transplantation (LDLT).[2,4]

From the first successful LT performed in 1967 to the late 1980s, only deceased-donor grafts were used.[2] However, as deceased organs from pediatric donors are rarely available, and liver size mismatch from deceased adult donors leads to longer waiting-list times, a reduced-size technique was developed by Bismuth et al. to increase the donor pool for pediatric patients.[5,6] Later, Pichlmayr et al.[7] developed a split technique using a deceased donor liver graft to use it for two pediatric patients. Even these approaches, which were aimed to widen and expand the deceased liver donor pool, were not adequate to meet the needs of patients in need of the liver. In many countries, a deceased liver donation was not widely adopted.

Living-Donor Liver Transplantation

To increase the donor pool, LDLT was introduced by Strong et al. in 1989.[8] Although LDLT was developed initially to decrease the gap between patients waiting for the liver and the scarcity of deceased organs in Western countries, it has become the primary form of LT in most Asian countries.[2] LDLT is a sophisticated and complex surgical procedure with a substantial risk of donor morbidity and mortality.[3,10,11] Intraoperative and postoperative complication rates for living donors are reported to be between 9% and 67%, respectively, and the mortality rate is estimated to be 0.08%–0.5%.[2,12] In addition, complications such as hepatic artery thrombosis, biliary leaks, and strictures are more common compared with most Asian countries.[12]

LDLT rates are low in most Western countries.[14] Of all LT activities, LDLT accounts for more than 90% of the transplantations in most Asian countries, 5% in the USA, and 4.3% in Europe.[12,15] One reason why LDLT is not being widely adopted in Northern America and Europe is the risk of morbidity and mortality in living donors. Another reason for low LDLT rates in Western societies is the high baseline levels of deceased organ supply due to increased awareness of organ donation compared with most Asian countries.[16]

Countries performing high volumes of LDLT developed new techniques. They made innovations such as left lateral segment graft use in pediatric patients to left lobe graft use in adults, right lobe graft use in LDLT, and dual graft use to overcome the organ shortage, whereas Western countries focused on promoting deceased organ donations.[1] In addition, some centers challenge the traditional 0.8% of graft/recipient weight ratio, suggesting that 0.6% can be safely adapted with portal pressure control, increasing the LDLT donor pool.[1,17] However, this ratio alone is not solely considered when determining the suitability because ideal graft size varies between the patients and depends on multiple factors including the recipient’s status.[12] Previously, aberrant biliary duct in the donor was considered a contraindication for LDLT because of the high risk of biliary complications. Advances in surgical approaches in biliary reconstruction with the use of routine microsurgical techniques have greatly decreased the risk of biliary complications from 21% to 5%, thereby increasing the number of potential donors for LDLT.[18]
Liver transplantation in developing countries

Indications of Liver Transplantation Vary by Region

Indications of LT across the globe change depending on the region. In the West, the most common indications for LT are hepatitis C virus (HCV) and alcohol-related liver disease (ALD), whereas, in the East, hepatitis B virus (HBV), HCV, and associated hepatocellular carcinoma (HCC) are the predominant cause.[1,18] Although preventive measures such as vaccination, screening, and antiviral treatment for HBV, and screening and treatment for HCV decreased the burden of chronic liver disease in some parts of the world, the prevalence of nonalcoholic fatty liver disease (NAFLD) and ALD increases globally.[19] The incidence of NAFLD increases in parallel with the increasing rates of obesity.

In the USA, the most common causes of LT were HCV, HCC, and ALD previously; however, recent reports indicate that in patients without HCC, ALD and NASH became the leading etiologies for LT.[20–22] In addition, NASH is becoming the leading cause of HCC, surpassing HCV, in the USA.[21,22]

Although the prevalence of HBV is declining, HBV is still intermediate to highly endemic in Asia.[1,23,24] Countries including China, India, Nigeria, and Indonesia consist of approximately half of the HBV infections worldwide.[25] In addition, the Western Pacific region consists of 60% of the HCCs worldwide, and China, Pakistan, India, Egypt, Russia, and the USA account for more than half of all HCV infections.[24–26]

In Turkey, although HBV has been the predominant cause of LT for the past 15 years, its frequency is decreasing. However, the frequency of NASH leading to LT is increasing, with reports indicating that 20% of patients having LT had NASH as opposed to 4% in the last decade.[27] NASH is the fastest growing cause of LT in Turkey and in many countries, with increasing incidence seen as parallel to increasing obesity rates.[27]

Living-Donor Liver Transplantation in Hepatocellular Carcinoma

The approach and selection of the donors for HCC vary between the regions, largely based on the differences between the use of LDLT and DDLT.[2] LT is indicated in patients with HCC within the Milan criteria (a single lesion ≤5 cm in diameter or no more than three lesions, none exceeding 3 cm in diameter).[28] Patients within Milan criteria undergoing LT have similar 4-year survival (75%) as patients with cirrhosis without HCC.[29] The University of California San Francisco (UCSF) criteria proposed that LT can be performed in HCC cases of only solitary tumors up to 6.5 cm or ≤3 nodules with the largest less than 4.5 cm and a total <8 cm.[30] However, these criteria are designed primarily to allocate deceased organs to maximize utilization and might be too restrictive.[2] In countries with high LDLT rates, the selection of patients can be expanded to include a select group of patients outside of Milan or UCSF criteria.[1,31] One advantage of LDLT in these conditions is that it does not affect the limited deceased donor pool and offers similar overall survival between DDLT and LDLT recipients.[1,12,33] Approximately 25% of the patients with cirrhosis and HCC are removed from the waiting list with the progression of the diseases, and LDLT offers the advantage of LT to be performed in an elective setting, thereby optimizing the timing of the operation and reducing waiting time.[2,12] However, the risk of morbidity and mortality of the donor should be considered while expanding the criteria to maximize the LT and protect both donor and recipient.[2]

Practice of Liver Transplantation Differs between the Developed and Developing Countries

The country’s legal framework determines the use and transplantation of deceased organs, which differs in most Asian countries compared with Europe and the USA. The practice of LT differs between the countries, reflecting their own health care policy, health expenditure per capita, socioeconomic status, cultural norms, religious beliefs, and societal attitudes toward LT.[1,2,34,35] Figure 1 shows the LDLT and DDLT activities in select countries in 2020.

The United Nations uses Human Development Index (HDI) to determine the development of the countries. HDI metric includes various factors, including gross national income per capita, life expectancy, and education. Many developing countries have a heterogeneous population, differing levels of education, and financial wealth among their residents with various religious compositions. Developing countries often have a poor collection of organ transplantation activity and limited resources to make the LT data publicly available. This is particularly evident in most countries in Africa and in some countries in Asia.[36] This nontransparent activity and the public lack of awareness prevent organ donation from reaching its maximum potential in these regions.

Despite the modern views encouraging and supporting deceased organ donation, traditional views still influence the majority of people.[1] In many Asian countries, traditions and religious beliefs play a major role in an individual’s life and in shaping the decision of organ donation.[1] Religions including Buddhism, Taoism, Confucianism, Shintoism, and Islam cautiously approach deceased organ donation.[1,13,36] Many Southeast Asian countries, except Singapore, have low-to-mid-
dle income and have similar challenges as faced by other developing
countries, such as the lack of infrastructure required for an organized
and well-coordinated organ transplantation network, registering potent-
tial donors to national programs for coordinating organ procurement
and promoting awareness in public.[17]

In Asia, the first successful LT was performed in Taiwan in 1984 by
Chen et al.[38] Among Asian countries, China is the only country with
DDLT being more common than LDLT, with 95% of donated livers
originating from deceased donors.[1,15] This practice stems from China’s
prior use of organs from nonvoluntaries, mainly from executed pris-
oners, which led to concerns over human rights and organ trafficking.
Eventually, starting from 2005, with continuous improvements in leg-
islation, China revised its organ transplantation practice on LDLT and
implemented WHO guiding principles. In 2015, China completely left
the practice of using organs from executed prisoners.[1,15,38]

Singapore has a developed economy with large health care expendi-
tures.[17] Singapore started using an opt-out system in 1987 with restric-
tive inclusion criteria such as only including those between 21 and 60
years old after a traumatic cause of death and allowing only kidney
procurement. This system has been modified multiple times over the
years and now allows a wide range of potential donors to be included
while allowing procurement of liver and other organs.[17]

Despite these legislations, DDLT remains very low in Singapore com-
pared with other developed countries (approximately 6 per million pop-
ulation [pmp] per year).[37,40] Main barriers are lack of awareness of
organ donation, discrepancies between donor referral and transplantation,
and cultural or religious beliefs.[17] To overcome organ scarcity, LDLT
plays a major role in Singapore.

In some developing countries with two-tier health care systems, such
as South Africa and India, wealthy patients often have easier access
to transplants than those with limited resources.[16] This modality also
augments the public mistrust of organ transplantation in those coun-
tries. Apart from religious beliefs, in some developing countries such
as India, the Philippines, Thailand, Indonesia, and Vietnam, DDLT rates
remain low. Other factors including lack of awareness of organ dona-
tion, lack of organized networks and national policies to facilitate organ
transplantations, and poverty are some other explanations.[1]

In India, the Transplantation of Human Organ Bill became law in 1995;
however, DDLT was not widely adopted, with most centers performing
LDLT to meet the needs of the patients.[2] In India, approximately 85%
of LT is derived from LDLT.[2] The low rates of DDLT in India are
thought to be a result of limited government policies across the country,
better understanding of brain death, limited identification of potential
donors, and lack of awareness and education of the public regarding
organ donation.[5]

The first DDLT in Turkey was performed by Haberal et al. in 1988.[41] In
addition, the same team performed the first left lobe LDLT procedure in
the world in an adult patient in 1990.[42] In Turkey, a study reported that
families of 23.4% of patients with brain death were permitted to use the
deceased organs to be used for transplantation between 2011 and 2014.
[16] Only one-fourth of LT in Turkey is derived from DDLT; however, as
a result of efforts to create public awareness of organ donation, 0.9 pmp
in 2001 increased to 7 pmp in 2019.[15,16]

Despite being a developed country, Japan shows low DDLT rates. First,
the use of a deceased donor in Japan in 1968 aroused public mistrust
because of the lack of proper documentation of the brain death of the
donor.[43] South Korea and China have been more successful in pro-
moting DDLT awareness and increasing the numbers of LT from de-
ceased donors over the last decade, and Iran and India are following
this trend slower.[18]

Consent Systems for Organ Donation

Opt-in (explicit consent) and opt-out (presumed consent) are two sys-
tems that exist for organ donation after death. In an opt-in system, poten-
tial donors need to actively give their consent for their organs to be
used after death, whereas in an opt-out system, no active consent is
needed, and individuals are presumed to give the consent unless they
specifically indicate the opposite.[36,44] Opt-out systems may increase
donation rates and may overcome challenges in deceased organ dona-
tion including culture and religious beliefs and transplant awareness.
[34,36] However, this system requires governmental support in building
the public infrastructure and may not be feasible in many countries with
limited resources.

In addition, hard consent, soft consent, and mandated consent exist and
are used in many countries.[16] Hard consent leaves no involvement of
family in the donation process, whereas soft consent involves family.
Mandated consent requires individuals to register their intent to donate
or not donate. This approach gives individuals to make a decision for
themselves.

Spain is an example of a country with a successful opt-out system (de-
spite it being practiced as a hybrid opt-in and opt-out), with the highest
number of donors per pmp (49.6 in 2019, compared with 36.8 in the
USA).[36,44] However, this highest pmp in Spain is not only a result of the
opt-out system but also a result of early identification of organ donors
by transplant coordinators, successful coordination of organ transplant
network, and an effective communication system with family members
with specifically trained professionals.[2]

Some reports argue that opt-in versus opt-out systems alone do not dif-
fer greatly in terms of increasing donor numbers; an opt-out system is
not imperative in all countries.[5,36] Multifaceted approaches, such as
legislative adaptation and consideration of health care resources and
population dynamics in each country, are necessary to overcome the
barriers to organ donation and maximize deceased organ utilization.[36,44]

Liver Transplant Registries

Compared with LLDT, DDLT requires a widespread organization from
coordination of organ procurement to allocating a recipient, and agen-
cies to oversee these activities, and requires more financial resources to
establish a successful network.[15] In the USA, National Organ Trans-
plant Act established the Organ Procurement and Transplantation Net-
work (OPTN) in 1984 to develop policies around waiting list, organ
donation and procurement, organ allocation, and transplantation. Unit-
ed Network Organ Sharing (UNOS) is a nonprofit, federally funded
organization that manages the OPTN.[2,20,44] In Europe, European Liver
Transplant Registry was established in 1985, and similar organizations
exist in China, Korea, and Japan.[5] In Europe, the European Directive,
Declaration of Istanbul, and the WHO guiding principles are imple-
mented to ensure the safety of living organ donors and report any ad-
verse effects after donation.[14,45,46] In some countries in Asia, the lack of
national LT registries and limited collection and uniform reporting of
data prevent having accurate outcomes of LT activity.[18] Despite suc-
cessful organizations in Europe (ELTR) and in the USA (UNOS), es-
ablishing a regional registry in Asia might be more difficult given the
available financial resources and geopolitical situation.
Liver Transplantation Center Volume on Outcomes

Transplant center volume is an important factor in LT outcome, with only a few reports investigating this topic. The majority of LDLT in Asia are performed in centers with high volume transplant numbers and having multidisciplinary care staff, given the complexity of the operation. High-volume transplant centers usually have less unfavorable outcomes compared with low-to-middle volume transplant centers. However, with the acuity of LT in certain conditions such as acute liver failure and socioeconomic and geographic limitations, access to such centers may not be feasible. In addition, it has been reported that patients are less likely to have LT in those programs and have a higher risk of mortality after LT. Narrowing this outcome gap is important to minimize the disparities across the transplant centers and to improve overall outcomes after LT at the national level.

Barriers to Liver Transplantation

Societal Beliefs, Traditions, and Religion

Traditions, beliefs, and religion play a strong role in daily life and decision-making in many countries and are important in public attitude toward organ transplantation, particularly deceased-organ donation.

Mistrust of Health Care System

Mistrust of the health care system and policymakers are another barrier in LT, with the belief that professionals have control over the organ transplantation process and legalities involving brain death for DDLT. Financial incentives and manipulation of transplant systems, as seen in South Africa in 2002 and Germany in 2013, resulted in dramatic decreases in donor numbers. In China, unethical procurement of donor organs from prisoners without informed consent has disrupted the public trust in organizations.

It was reported in 2007 that up to 10% of organ transplants worldwide are involved in organ trafficking or patients who travel abroad to buy organs from vulnerable people. Declaration of Istanbul was developed to prevent human organ trafficking and to prevent the exploitation of poor individuals/countries being organ donors to recipients of wealthy individuals/countries in 2008. To overcome these barriers and regain public trust, we recommend transparency in every step of organ transplantation.

Conclusion

With the success of the LT, the demand for liver exponentially increases while the number of donors remains relatively stable. The practice of LT varies widely depending on the region. To maximize the pool of available organs, the East should focus on improving deceased liver donation, whereas the West needs to improve living-donor liver donation. Efforts must be made to approach the barriers in LT in multifaceted ways as LT is a life-saving treatment.

References

1. Chen CL, Kabling CS, Concejero AM. Why does living donor liver transplantation flourish in Asia? Nat Rev Gastroenterol Hepatol 2013;10(12):746-751.
2. Shukla A, Vadeyar H, Rela M, Shah S. Liver Transplantation: East versus West. J Clin Exp Hepatol 2013;3(3):243-253.
3. Cameron AM, Ghoibrial RM, Yersiz H, Farmer DG, Lipshutz GS, Gordon SA, et al. Optimal utilization of donor grafts with extended criteria: A single-center experience in over 1000 liver transplants. Ann Surg 2006;243(6):748-755.
4. Lennerling A, Lovén C, Dor FJ, Ambagtsheer F, Duerinckx N, Fruzena M, et al. Living organ donation practices in Europe - results from an online survey. Transpl Int 2013;26(2):145-153.
5. Lobritto S, Kato T, Emond J. Living-donor liver transplantation: Current perspective. Semin Liver Dis 2013;32(4):333-40.
6. Muhammad H, Zaffar D, Tehreem A, Ting PS, Simsek C, Turan I, et al. an update on usage of high-risk donors in liver transplantation. J Clin Med 2021;11(1):215.
7. Bismuth H, Houssin D. Reduced-sized orthotopic liver graft in hepatic transplantation in children. Surgery 1984;95(3):367-370.
8. Pichlmayr R, Ringe B, Gubernatis G, Hauss J, Bunzendahl H. Transplantation einer Spenderleber auf zwei Empfänger (Splitting-Transplantation)—Eine neue Methode in der Weiterentwicklung der Lebersegmenttransplantation [Transplantation of a donor liver to 2 recipients (splitting transplantation)]—a new method in the further development of segmental liver transplantation. Langenbecks Arch Chir 1988;373(2):127-130. [German]
9. Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med 1990;322(21):1505-1507.
10. Cheah YL, Simpson MA, Pompessoni JJ, Pomfret EA. Incidence of death and potentially life-threatening near-miss events in living donor hepatic lobectomy: A world-wide survey: Death and near-miss events. Liver Transpl 2013;19(5):499-506.
11. Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: Multidisciplinary approach to improve outcome. ISRN Hepatol 2014;2014:706945.
12. Wakade VA, Mathur SK. Donor safety in live-related liver Transplantation. Indian J Surg 2012;74(1):118-126.
13. Kaido T, Uemoto S. Does living donation have advantages over deceased donation in liver transplantation? J Gastroenterol Hepatol 2010;25(10):1598-603.
14. Trotter JF, Cárdenas A. Liver transplantation around the world. Liver Transpl 2016;22(8):1059–1061.
15. Rela M, Rammohan A. Why are there so many live donors from living donors in Asia and so few in Europe and the US? J Hepatol 2021;75(4):975-980.
16. Akbulut S, Yılmaz S. Liver transplantation in Turkey: Historical review and future perspectives. Transplant Rev 2015;29(3):161-167.
17. Kaido T, Mori A, Ogura Y, Hata K, Yoshizawa A, Iida T, et al. Lower limit of the graft-to-recipients weight ratio can be safely reduced to 0.6% in adult-to-adult living donor liver transplantation in combination with portal pressure control. Transplant Proc 2011;43(6):2391-2393.
18. Hibi T, Wei Chieh AK, Chi-Yan Chan A, Bhangi P. Current status of liver transplantation in Asia. Int J Surg 2020;82S:4-8.
19. Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Cln Gastroenterol Hepatol 2020;18(12):2650-2666.
20. Alqahtani SA, Larson AM. Adult liver transplantation in the USA. Curr Opin Gastroenterol 2011;27(3):240-247.
21. Goldberg D, Ditah IC, Saeian K, Lalhezari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis c virus infection, nonalcohol-
ic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation in the United States. JAMA Netw Open 2020;3(2):e1920294.

23. Wong MCS, Huang J, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol 2019;16(1):57-73.

24. Razavi H. Global epidemiology of viral hepatitis. Gastroenterol Clin North Am 2020;49(2):179-189.

25. Jefferies M, Raff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases 2018;6:589-599.

26. Blach S, Terrault NA, Tacke F, Gamkrelidze I, Craxi A, Tanaka J, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol 2022;7(5):396-415.

27. Serin A, Sahin T, Arikan BT, Emek B, Bozkurt B, Tokat Y. A changing etiologic scenario in liver transplantation: A single-center cohort study from Turkey. Transplant Proc 2019;51(7):2416-2419.

28. Mazzafzero V, Regalia E, Doci R, Andreola S, Pulvirenti A, Rozzeti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693-700.

29. Mahmoud N. Selection for liver transplantation: Indications and evaluation. Curr Hepatol Rep 2020;19(3):203-212.

30. Yao FY, Ferrell L, Bass NM, Watson JJ, Baccetti P, Venoook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33(6):1394-1403.

31. Petrowsky H, Kim KH, Tokat Y. Editorial: Living-donor liver transplantation: why the Sun rises in the East and sets in the West? Curr Opin Organ Transplant 2019;24(5):620-622.

32. Florman S, Miller CM. Live donor liver transplantation. Liver Transpl 2006;12(4):499-510.

33. Muhammad H, Gurakar M, Ting PS, Alsughayer AM, Luu H, Zaffar D, et al. Long-term outcomes of living donor versus deceased donor liver transplant for hepatocellular carcinoma in the United States. Exp Clin Transplant 2022;20(3):279-284.

34. Ezaz G, Lai M. How the “Opt-In” option optimizes organ donation rates. Dig Dis Sci 2019;64(5):1067-1069.

35. Saab S, Saggi SS, Akbar M, Choi G. Presumed consent: A potential tool for countries experiencing an organ donation crisis. Dig Dis Sci 2019;64(5):1346-1355.

36. Etheredge HR. Assessing global organ donation policies: Opt-in vs opt-out. Risk Manag Healthc Policy 2021;14:1985-1995.

37. Yeow M, Bonney GK, Kow WCA, Wee P, Madhavan K, Iyer SG. Liver transplantation in Singapore: Challenges and strategies of low- to mid-volume centers. Transplantation 2022;106(5):895-897.

38. Chen YS, Chen CL, de Villa VH, Wang CC, Wang SH, Liu PP, et al. Living-Donor Liver Transplantation in Taiwan. In: Kitajima M, Shimazu M, Wakabayashi G, Hoshide K, Tanabe M, Kawachi S, editors. Current Issues in Liver and Small Bowel Transplantation. Tokyo: Springer Japan; 2002. pp. 13–21. (Keio University International Symposium for Life Sciences and Medicine).

39. Shi BY, Liu ZJ, Yu T. Development of the organ donation and transplantation system in China. Chin Med J (Engl) 2020;133(7):760-765.

40. Kwok TK, Lew TK, Tan HL, Kong S. The transplantable organ shortage in Singapore: has implementation of presumed consent to organ donation made a difference? Ann Acad Med Singap 2009;38(4):346-348.

41. Haberal M, Sert S, Aybasi N, Gulay H, Gokce O, Arslan G, et al. Living donor kidney transplantation. Transplant Proc 1988;20(1 Suppl 1):353-355.

42. Haberal M, Buyukpamukcu N, Telatar H, Bilgin N, Arslan G, Simsek H, et al. Segmental living liver transplantation in children and adults. Transplant Proc 1992;24(6):2687-2689.

43. Kimura R. Organ transplantation and brain-death in Japan. Cultural, legal and bioethical background. Ann Transplant 1998;3(3):55-58.

44. Lewis A, Koukoura A, Tsianos GI, Gargavanis AA, Nielsen AA, Vassiliadis E. Organ donation in the US and Europe: The supply vs demand imbalance. Transplant Rev 2021;35(2):100585.

45. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism (2018 Edition). Transplantation 2019;103(2):218-219.

46. World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation 2010;90(3):229-233.

47. Alqahtani SA, Stefanova M, Kabbara KW, Younossi L, Mishra A, Younossi Z. Liver transplant center size and the impact on clinical outcomes and resource Utilization. Transplantation 2022;106(5):988-996.

48. Axelrod DA, Guidinger MK, McCullough KP, Leichtman AB, Punch JD, Merion RM. Association of center volume with outcome after liver and kidney transplantation. Am J Transplant 2004;4(6):920-927.

49. Edwards EB, Roberts JP, McBride MA, Schulak JA, Hunsicker LG. The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. N Engl J Med 1999;341(27):2049-2053.

50. Ozhathil DK, Li YF, Smith JK, Tseng JF, Saidi RF, Bozorgzadeh A, Shah Z. Liver transplant center size and the impact on clinical outcomes and resource Utilization. Transplantation 2022;106(5):988-996.

51. Sidley P. South African doctors charged with involvement in organ trade. BMJ 2004;329(7459):190.

52. Paul NW, Caplan A, Shapiro ME, Els C, Allison KC, Li H. Human rights violations in organ procurement practice in China. BMC Med Ethics 2017;18(1):11.

53. Shimazono Y. The state of the international organ trade: a provisional picture based on integration of available information. Bull World Health Organ 2007;85(12):955-962.

54. International registry in organ donation and transplantation (Internet). 2022 Accessed on April 28, 2022. Available at: https://www.iodat.org/